In particular, autoantibodies against different gangliosides, neurofascin isoforms (NF155 and NF140/186), Contactin 1, and CASPR1 have been described in approximately 10% of CIDP patients and could be helpful to distinguish different CIDP subtypes or (para-) nodopathies (79, 80, 81) as well as potentially assist disease activity monitoring (82). This evidence concerns the gene CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy.